In January 1996, Merck & Co. proved that<unk>  was a clinically efficient drug based on data from human trials. They were able to show that<unk> , when used with two other anti-HIV drugs, could significantly reduce the HIV viral load. Study 035 The study's goal was to show the different effects of different antiviral treatments. 97 patients were randomly assigned to one of the three groups:<unk>  monotherapy, AZT and lamivudine, or all three agents. Eligible patients were those who received AZT for at least 6 months and have CD4 cell counts between 50 and 400, viral loads of at least 200,000 copies/mL, and had no prior antiretroviral therapy with protease inhibitor or lamivudine. The results of the study showed that the most effective treatment was the three drug treatment. After 24 weeks of treatment, 24 patients of the 28 patients who were treated with the three drugs were able to have viral load levels have less than 500 copies/ml. 12 out of 28 patients under<unk>  monotherapy reached 500 copies/ml, and none of the thirty patients in AZT and lamivudine group got below 500 copies. ACTG 320 This study took a look at clinical efficiency of the different treatments. Patients had to have CD4 cell counts less than 200 and at least 3 months of AZT therapy before the trials. 1156 patients with a mean of 87 CD4 cell counts and mean viral load of 100,000 copies/ml were randomized to one of the two groups: AZT plus lamivudine or AZT plus lamivudine plus<unk> . Just like Study 035, patients couldn't be in the study if they had prior protease inhibitor treatment or lamivudine for more than one week. The end point of the study was death or development of opportunistic infections. After 38 weeks, 6% of the people in the three-drug group died while 11% of the people died in the two-drug group. There were higher CD4 cell counts and less viral load in patients assigned to the three-drug group, proving that a three-drug treatment is more efficient than a two-drug one.
Indinavir
Saquinavir
Fosamprenavir
Entecavir
Coronavir
Abacavir
Telaprevir
Fostemsavir